GLUT3 enhances chemosensitivity in glioblastoma by transporting temozolomide and capecitabine.

ABSTRACT: Glioblastoma multiforme (GBM), the most aggressive brain cancer, is highly resistant to chemotherapy, which profoundly affects patient survival and prognosis. Temozolomide (TMZ), the sole first-line chemotherapeutic agent for GBM, faces substantial challenges in overcoming this resistance. Despite the belief that TMZ is well-absorbed in the small intestine and can effectively cross the blood-brain barrier due to its small molecular size, emerging evidence suggests that its uptake is not merely through passive diffusion across the lipid bilayer but is regulated by Wnt signaling. However, the precise mechanism governing TMZ uptake remains elusive. GLUT3, which is highly expressed in GBM and primarily functions as a glucose transporter, has emerged as a promising therapeutic target. This stud

SUBMITTER: Diao H 

PROVIDER: S-EPMC12354831 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature